Imfinzi (Durvalumab)
durvalumab 120 mg/2.4 mL injection, 2.4 mL vial · INJECTION · PBS code 15330W
STREAMLINEDWhat it costs
AU$860.99 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-04-01.
- • Repeats: 5.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Limited-stage small cell lung cancer
Patient must have received chemoradiation therapy (CRT); AND
The condition must not have progressed following CRT; AND
Patient must have had a WHO performance status of no greater than 1 at treatment initiation with this drug for this condition; AND
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND
The treatment must not exceed 24 months in total for this condition, measured from the initial dose, or must not extend beyond disease progression, whichever comes first.
Sponsor: AstraZeneca Pty Ltd ABN 54 009 682 311
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.